Overview
- 37 inspections across 34 sites are on record.
- 54 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2011-03-30.
At a glance
Inspections
37
Sites
34
Observations
54
Career since
Feb 2008
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Theragenics Corporation | 30 Mar 2011 | ||
| Janssen Pharmaceuticals, Inc. | 18 Feb 2011 | ||
| GlaxoSmithKline LLC | 27 Jan 2011 | ||
| The Ritedose Corporation | 30 Sep 2010 | ||
| Isomedix Operations Inc | 26 Aug 2010 |
Sites inspected
Theragenics CorporationBuford, United States1 insp.
Janssen Pharmaceuticals, Inc.Athens, United States1 insp.
GlaxoSmithKline LLCAiken, United States1 insp.
The Ritedose CorporationColumbia, United States1 insp.
Isomedix Operations IncSpartanburg, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Lareese K Thomas4 shared
Tamika D Cathey3 shared
Thomas R Berry3 shared
Trang N Cox2 shared
Hai Lien T Phung2 shared
Gabriel R Mclemore2 shared
Babatunde D Babalola2 shared
Viviana Matta1 shared
Dellarese L Herbert1 shared
Tammara A Stephens1 shared
Full investigator report
Get the verbatim findings behind Ibad U Khan's 54 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site